Completed PHASE3 INTERVENTIONAL 4-arm NCT02624505

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.

Sponsor: Cipla Ltd.

Conditions Bronchial Asthma

Interventions 180 mcg Reference Product 90 mcg Reference Product 90 mcg Test Product Placebo

Updated 8 times since 2017 Last updated: Jul 23, 2019 Started: Dec 31, 2015 Primary completion: Oct 31, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Bronchial Asthma and is currently completed. Cipla Ltd. leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jun 2018 — Aug 2019 [monthly]

Unknown Status PHASE3

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Feb 2017 — Apr 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cipla Ltd.

Data source: Cipla Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States